Sigrid V. Carlsson, MD, PhD, MPH, presented “Who Needs a Prostate Biopsy? Risk-stratification Strategies Before Prostate Biopsy” during the 24th Future Directions in Urology Symposium in August 2024 in Colorado Springs, Colorado.
How to cite: Carlsson, Sigrid V. “Who Needs a Prostate Biopsy? Risk-stratification Strategies Before Prostate Biopsy.” August 2024. Accessed Nov 2024. https://grandroundsinurology.com/who-needs-a-prostate-biopsy-risk-stratification-strategies-before-prostate-biopsy/
Who Needs a Prostate Biopsy? Risk-stratification Strategies Before Prostate Biopsy – Summary
Sigrid V. Carlsson, MD, PhD, MPH, discusses the evolving paradigm in prostate cancer diagnostics, moving away from the traditional model where an elevated prostate-specific antigen (PSA) level directly leads to a biopsy. In this 8-minute talk, she emphasizes the importance of incorporating risk stratification methods before proceeding to biopsy, which helps reduce unnecessary interventions.
Dr. Carlsson discusses current guidelines that recommend using MRI as part of the initial biopsy strategy, with a more mandatory role in repeat biopsy settings if it has not previously been performed. Risk calculators provide a cost-effective and accessible means to estimate the likelihood of high-grade disease, further refining the decision-making process.
The presentation also highlights the rapid advancement in biomarkers and the integration of artificial intelligence (AI) in improving MRI interpretation and enhancing prostate cancer diagnostics’ accuracy and efficiency.
The Future Directions in Urology Symposium (FDUS) is an annual urology think tank and non-CME educational summit that brings together industry figures and experts to discuss the current state of genitourinary care and define future directions in treatment. Dr. Dreicer delivered this educational activity during the 24th iteration of the meeting in August 2024 in Colorado Springs, Colorado.
ABOUT THE AUTHOR
Sigrid V. Carlsson, MD, PhD, MPH, is Director of Clinical Research at Memorial Sloan Kettering Cancer Center’s (MSKCC) Josie Robertson Surgery Center and Assistant Attending Epidemiologist, with dual appointments in MSKCC’s Departments of Surgery (Urology Service) and Epidemiology and Biostatistics. Her line of research focuses on screening and early detection of prostate cancer, including multiplex testing and risk-stratified strategies that incorporate clinical information, biomarkers and magnetic resonance imaging, as recently funded by an NIH/NCI U01 award (PI: Carlsson).
Dr. Carlsson also serves as Associate Professor of Experimental Urology affiliated with the Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, in Sweden, where she is an investigator of two large randomized controlled trials of prostate cancer screening (GOTEBORG-1&2), as recently published in the New England Journal of Medicine (Hugosson J, et al. N Engl J Med 2022). In addition, Dr. Carlsson is Adjunct Senior Lecturer in the Department of Translational Medicine in the Division of Urological Cancers in the Medical Faculty at Lund University, Lund, Sweden.
Dr. Carlsson recently completed a K22 career development award from the NIH/NCI to improve shared decision-making for breast and prostate cancer screening. She serves on the National Comprehensive Cancer Network (NCCN) and is a panel member for the American Urological Association (AUA) guidelines for early detection of prostate cancer. Before pursuing postdoctoral studies in urologic oncology at MSKCC, Dr. Carlsson was a physician in Sweden. She earned her MD and PhD from Gothenburg University in Sweden and earned an MPH from Harvard TH Chan School of Public Health in Boston, Massachusetts.
